Erasca (ERAS) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Pipeline differentiation and scientific rationale

• Focus on optimizing both potency and pharmacokinetics (PK) to achieve a 'Goldilocks zone' for efficacy and safety in pan-RAS and pan-KRAS inhibitors.

• ERAS-0015 demonstrates 5-10x higher potency than RMC-6236 in preclinical models, with lower required doses for tumor regression.

• Enhanced PK profile includes higher oral bioavailability, longer half-life, and lower clearance, potentially reducing on-target toxicity.

• Preferential tumor biodistribution may offer a therapeutic window advantage, especially in tumors overexpressing CypA.

• Pan-KRAS inhibitor ERAS-4001 targets the Switch II Pocket and shows activity against both GDP and GTP states, supporting combination strategies.

Clinical progress and early data

• Phase 1 AURORAS-1 study of ERAS-0015 shows multiple partial responses at low doses, including a confirmed response in a heavily pretreated NSCLC patient.

• Safety profile remains favorable with no dose-limiting toxicities and predominantly low-grade adverse events.

• Dose escalation ongoing up to 40 mg, with data on dozens of patients expected in the first half of the year.

• Patient enrollment includes a balanced distribution across major tumor types, with no single histology dominating.

• Dose expansion cohorts planned for the second half, focusing on pancreatic and lung cancers, with combination studies under consideration.

Competitive landscape and development strategy

• Differentiation from competitors may be established by achieving a 10% or greater absolute improvement in objective response rate (ORR) and potential durability advantages.

• Both pan-RAS and pan-KRAS assets provide flexibility to adapt to evolving treatment landscapes and unmet needs.

• Combination of pan-RAS and pan-KRAS inhibitors is scientifically rational and may offer synergistic benefits.

• Data-driven approach will determine advancement of one or both assets, with monotherapy and combination strategies in development.

• BOREALIS-1 phase 1 study for ERAS-4001 is advancing, with data expected in the second half and dose expansions planned for 2027.